The global orphan drugs market should reach $315.6 billion by 2024 from $127.5 billion in 2017 at a compound annual growth rate (CAGR) of 13.8% for the forecast period of 2017 to 2024. This report investigates recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024.
An increasingly older population, rising demand for efficient and affordable antibacterial drugs and the growing number of multi-drug resistant bacterial strains are some of the key factors which are driving the global antibacterial drugs market.
The rising burden of several infectious and non-infectious diseases, an increasing government and non government support for vaccine development, and increasing research requests and current underdevelopment are likely to augment Global Vaccine Market growth.
The global human insulin market is predicted to garner a CAGR of 12.1% during the forecast period (2017-2023), Market Research Future (MRFR) reveals in the latest report. Human insulin can be defined as a synthetic, which is largely manufactured in laboratories by developing insulin protein with E. coli bacteria.
Growing use of enzymes in the treatment of chronic diseases, increasing demand for active therapeutics and rising incidences of digestive enzyme disorders are some of the key factors driving the growth of the specialty enzymes market in pharmaceuticals, biotechnological science and diagnostics.
Global typhoid treatment market is rising gradually with a substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. The growth in the market can be attributed by the prevailing cases of typhoid across the globe.